H. Lundbeck A/S has received marketing authorization from Japan's Ministry of Health, Labour and Welfare for Vyepti (eptinezumab), expanding the availability of an intravenous CGRP-targeted preventive therapy for adults with migraine. The approval also marks Lundbeck's first independent product launch in Japan, giving the company a larger direct commercial role in one of Asia's major healthcare markets.

Lundbeck's Japanese approval of Vyepti adds another regulatory milestone to the company's expansion of its migraine portfolio across Asia, while highlighting the growing role of targeted biologic therapies in migraine prevention.

The authorization covers eptinezumab for the prevention of migraine attacks in adults. Eptinezumab is a humanized monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a signaling molecule associated with migraine. Unlike orally administered preventive medicines, Vyepti is delivered intravenously, with clinical studies evaluating dosing at 12-week intervals.

The Japanese decision follows an application accepted by the country's Ministry of Health, Labour and Welfare in November 2025. That filing was supported by data from the Phase III SUNRISE program, which evaluated eptinezumab in a predominantly Asian population with chronic migraine.

SUNRISE enrolled 978 participants, including 621 from Asia. Both the 100 mg and 300 mg eptinezumab groups met the trial's primary and key secondary efficacy endpoints, with greater reductions in monthly migraine days than placebo during the first 12 weeks. The researchers also reported that safety outcomes were similar across treatment groups.

Evidence specifically involving Japanese patients comes from the SUNSET long-term extension study. Among 159 treated Japanese participants, 141 completed the 60-week extension. Researchers reported maintained reductions in monthly migraine days and no new safety signals during the extension period.

The broader clinical program also includes PROMISE-1 and PROMISE-2, which studied eptinezumab in episodic and chronic migraine respectively, and DELIVER, a Phase IIIb study involving adults who had experienced two to four previous preventive treatment failures. In PROMISE-1, eptinezumab 100 mg and 300 mg significantly reduced monthly migraine days compared with placebo.

Japan represents a significant market for migraine prevention. Lundbeck cites estimates that migraine affects approximately 8.4% to 11.0% of the Japanese population and contributes substantially to lost productivity. The company's authorization therefore has implications beyond regulatory access, particularly as healthcare systems consider the economic burden associated with recurrent migraine and inadequate disease control.

The announcement also has a commercial significance for Lundbeck. The company said the approval enables its first independent launch in Japan as the marketing authorization holder, following 25 years of activity in the country. The move follows Vyepti approvals in other Asian markets, including South Korea in May 2026.

For the broader healthcare technology and life-sciences ecosystem, the development illustrates how pharmaceutical companies are increasingly combining targeted biologics, region-specific clinical evidence and direct commercialization strategies when expanding specialty medicines into Asian markets.

Market Landscape

Migraine remains a major neurological health burden globally. The World Health Organization says headache disorders are among the most common neurological disorders and that migraine ranked third in overall neurological disease burden by age-standardized DALYs in 2021.

The competitive landscape for migraine prevention includes several therapeutic approaches, including CGRP-targeted monoclonal antibodies, oral preventive medicines and other established interventions.

Eptinezumab's clinical development is differentiated by its intravenous delivery model and evidence across episodic migraine, chronic migraine and patients with previous preventive treatment failures. Clinical trials have also examined longer-term treatment effects and patient-reported outcomes.

Japan's approval places Vyepti within an expanding Asian migraine-treatment market where regulators and healthcare providers are evaluating evidence generated across both global and regional patient populations.

Strategic Outlook

The Japanese authorization demonstrates the increasing importance of localized clinical evidence when pharmaceutical companies expand specialty therapies internationally.

For Lundbeck, the launch also represents a shift toward greater direct commercial control in Japan. The company's earlier regulatory submissions across Japan, China and South Korea were part of a broader Asian expansion strategy.

The next phase will depend on market access, physician adoption, reimbursement and the ability to integrate preventive migraine treatment into routine neurological care. Clinical evidence alone does not determine patient access; healthcare-system economics and treatment pathways also influence how quickly newly authorized therapies reach eligible patients.

Top Insights

• Japan has authorized Vyepti for adults with migraine, expanding access to Lundbeck's intravenous CGRP-targeted preventive treatment.
• SUNRISE provided Asian clinical evidence, with 621 of 978 trial participants coming from Asia and both studied doses meeting key efficacy endpoints.
• SUNSET added Japanese long-term data, with 159 participants treated and no new safety signals identified over the 60-week extension.
• Lundbeck gains a direct commercial role, describing the Japanese authorization as its first independent product launch in the country.
• CGRP therapies are reshaping migraine prevention, adding targeted biologic approaches alongside established oral and non-drug treatment strategies.

Get in touch with our MarTech Experts.